Olivia Newton-John Cancer Research Institute

Call Directions Website

Olivia Newton-John Cancer Research Institute We want to see a future where we better understand cancer so that we can make it a manageable disease.

ONJCRI is an independent medical research institute dedicated to developing cancer therapies that are more effective, tolerable and accessible for all patients. To achieve this, our teams of laboratory-based researchers and patient-focused clinicians work together to discover and translate research breakthroughs to deliver better health outcomes for patients. Our research is primarily focused on investigating treatments for cancers of the gastrointestinal tract, pancreas, stomach, bowel, colon, breast, and brain. In 2021, we proudly partnered our researchers and clinicians with patients from many areas in Australia to lead 12 Institute-sponsored clinical trials giving patients access to potential new treatments including immunotherapies and personalised medicine.

🎓 Last week, our students came together for the annual ONJCRI Student Retreat.  Organised by our dynamic Student Society...
23/10/2026

🎓 Last week, our students came together for the annual ONJCRI Student Retreat.

Organised by our dynamic Student Society, this year’s retreat was at Melbourne Zoo.

The program included presentations by students and senior members of the institute, great conversations and the opportunity to get up close with the zoo's animal residents 🦁

Congratulations to Liam Neil on receiving the awards for Best 10-minute Presentation and People’s Choice, and to Lily Fraser on receiving the Best Science Bites award.

Thank you to our Student Society for organising such an engaging event and to New England Biolabs for their support.

🔬Learn more about studying at ONJCRI: https://ow.ly/kxBY50ZZzae


La Trobe University

💛  We are thrilled to share that Bendigo Woollen Mills has raised over $30,000 for vital breast cancer research at ONJCR...
21/10/2026

💛 We are thrilled to share that Bendigo Woollen Mills has raised over $30,000 for vital breast cancer research at ONJCRI.

Located in the heart of the Victorian Goldfields region, Bendigo Woollen Mills has been in operation for over 40 years and is the largest manufacturer of hand-knitting yarn in Australia.

🧶 This is Bendigo Woollen Mills’ second fundraiser for our institute. The funds raised this year will support research into metastatic breast cancer.

If caught early, breast cancer can be treated well with existing therapies and treatments in most cases; however, metastatic breast cancer remains harder to treat and has a worse prognosis. This is why research into new treatment strategies for these advanced types of breast cancer is vital.

Bendigo Woollen Mills General Manager Kai Crosson shares the motivation behind supporting life-saving breast cancer research:

“We're so grateful to have seen the outcomes improve for initial diagnosis for breast cancer sufferers and all the support now available.

“We wanted to support research into metastatic breast cancer, an area that perhaps wasn't as well known and well-funded.”

Thank you to our friends at Bendigo Woollen Mills for their significant and continued support of our research.

➡️ Learn more about the ways you can support our research: https://ow.ly/okG550ZYNNa

A study led by researchers at ONJCRI and the Peter Doherty Institute for Infection and Immunity has generated findings t...
16/10/2026

A study led by researchers at ONJCRI and the Peter Doherty Institute for Infection and Immunity has generated findings that could revolutionise cancer treatment and vaccine design.

mRNA-lipid nanoparticles (LNPs) transformed how vaccines are delivered to humans when they became widely used during the COVID-19 pandemic.

They are tiny parcels, ~800 times smaller than the width of a human hair, made of fatty acids (lipids) and containing cargo (mRNA) that needs to be delivered inside the body to generate a treatment response (for example, immunity to a virus).

mRNA-LNPs are being investigated as candidates for “cancer vaccines” that would deliver mRNA cargo to boost the patient’s immune system and empower it to kill cancer more effectively.

The research team analysed 327 blood samples from 73 participants who received Moderna, Pfizer, or an investigational COVID-19 mRNA vaccine.

Dr Yi (David) Ju, senior author of the paper published in ACS Nano and laboratory head at ONJCRI, said:

“mRNA vaccines do not all behave the same way in the bloodstream. We found differences in how quickly their mRNA and lipid components declined, and how long sections of the mRNA remained intact.”

The findings provide strong clues on how to make the vaccines more stable, likely making them much more efficient so that patients can receive lower vaccine doses that cause fewer side effects.

By establishing a framework to compare mRNA-LNP platforms in humans, the study can help guide the development of more effective mRNA-based medicines.

➡️ Read more: https://ow.ly/2PG650ZXquy
📘 Read the paper: https://ow.ly/Pnbz50ZXquB

La Trobe University, The Peter Doherty Institute for Infection and Immunity


📸 L-R: Prof Stephen Kent (Peter Doherty Institute), Dr Yi (David) Ju and Dr Shiyao Li (ONJCRI, La Trobe University)

💛  National Carers Week When Nicole was diagnosed with Acute Lymphoblastic Leukaemia (a type of blood cancer) at just fo...
14/10/2026

💛 National Carers Week

When Nicole was diagnosed with Acute Lymphoblastic Leukaemia (a type of blood cancer) at just four years old, her parents suddenly found themselves in the new and challenging role of carers.

Nicole’s father, Anthony, recalls:

“Luisa (Nicole’s mother) became Nicole’s full-time carer, supporting her through treatment, while Nicole’s sisters helped maintain a sense of normality and family connection. We knew the road ahead would be difficult, but we were determined to face it together.”

The family was living in Albury at the time, and there was no cancer centre in the border city.

“Living 320 kilometres from the Royal Children’s Hospital in Melbourne added significant emotional, physical and financial pressure.

“Travelling to Melbourne for treatment meant time away from home, while we also had to consider our other daughters, including our youngest, who was just two years old.

“We had to lean on relatives to help with taking our other children to and from school and the general day-to-day responsibilities.”

Today, Nicole is 30 years old, cancer-free and is part of our Patient Advocacy Program, sharing her lived experience to support childhood blood cancer research in Dr Teresa Sadras’ laboratory.

Nicole’s parents’ advice to other people currently on the carer journey:

“Stay strong, take things one day at a time and lean on your family and support network. Caring for a child with cancer is emotionally and physically exhausting, and it is okay to have difficult days.

“We always held onto the saying, “There is a Light at the End of the Tunnel.” That hope helped carry us through, and today we are incredibly grateful that Nicole is in remission.”

Thank you to Nicole and her parents for generously sharing their story to shine a light on the important role of carers this National Carers Week!


Carers Australia

🧬 Dr Conor Kearney is a laboratory head who specialises in sophisticated gene-editing techniques to advance our understa...
14/10/2026

🧬 Dr Conor Kearney is a laboratory head who specialises in sophisticated gene-editing techniques to advance our understanding of cancer.

Our DNA contains genes, which act like instructions that help our cells grow, function and stay healthy.

Dr Kearney’s team recently used CRISPR technology to screen 20,000 genes in human cells. By switching off genes one at a time, they could observe what each gene does and how silencing it affects the cells.

And through this research, they discovered a promising new breast cancer treatment target 🎯

A specific gene was found to drive cancer growth and block powerful immune cells, called Natural Killer (NK) cells, from eliminating cancer.

“This is particularly interesting because drugs that target the protein made by this previously are already being investigated in clinical trials.”

🔬 In his next project, Dr Kearney will collaborate with ONJCRI breast cancer researchers to better understand how aggressive breast cancers use this mechanism to survive NK cell attack.

The team will explore whether blocking the protein this gene produces can reduce cancer cell growth and make cancer more vulnerable to the immune system.

“By understanding how cancer evades NK cells, we hope to uncover new treatment strategies that could ultimately benefit patients with different forms of breast cancer.”

This upcoming project is a collaboration with Dr Bhupinder Pal, clinician–scientist Dr Belinda Yeo and PhD student Liam Neil.



📸 Dr Conor Kearney with PhD student Akash Srivaths, who conducted the 20,000-gene screen together.

🔬 Powering cancer research through lived experienceRay has been a long-standing patient advocate on ONJCRI’s Patient Adv...
11/10/2026

🔬 Powering cancer research through lived experience

Ray has been a long-standing patient advocate on ONJCRI’s Patient Advocacy Program.

He is a survivor of mouth, oesophageal, and prostate cancer and has witnessed bowel and breast cancer affect his family.

This is what drives his passion to support cancer researchers in their work. Ray’s commitment is to make the next person’s cancer journey a little easier.

🗣️ “I help bring the patient voice into research discussions, sharing what it’s like to navigate diagnosis, treatment and recovery. It’s about making sure research is practical, patient-centred and meaningful.”

“Longstanding advocacy is about keeping research focused on people’s real needs, what they can understand, access and act on, as well as what they may experience along the way.”

Ray has contributed by sharing his personal insights and experiences with researchers and by offering perspectives on what makes a difference in the daily life of a cancer patient.

In 2018, Ray helped deliver Patient Advocate Training, helping other community members participate in advocacy. Throughout the years, He has seen the program grow steadily.

“It is encouraging to see how far patient advocacy has come."

Ray stays deeply connected to his community by being active with several clubs. He enjoys golf, walking, live theatre and listening to music.

The Patient Advocacy Network is honoured to have Ray, helping advance cancer research at ONJCRI through his lived experience.

➡️ Do you have a connection to cancer, and would like to use your voice to support research?

Learn more about our Patient Advocacy Program: https://ow.ly/xQ5b50ZW8iR

🎉 Prof Marco Herold elected AAHMS Fellow  Congratulations to our CEO, Professor Marco Herold, on being elected a Fellow ...
09/10/2026

🎉 Prof Marco Herold elected AAHMS Fellow

Congratulations to our CEO, Professor Marco Herold, on being elected a Fellow of the Australian Academy of Health and Medical Sciences.

Election to the Academy is one of the highest honours in the fields of health and medical sciences in Australia, recognising outstanding achievements and exceptional contributions to improving health and advancing medical research.

This Fellowship is a recognition of Prof Herold’s scientific leadership and contributions to the field of cancer research.

Alongside his CEO duties at ONJCRI, Prof Herold is also a laboratory head at the institute and Head of La Trobe University’s School of Cancer Medicine.

He is internationally recognised for his leadership in genome engineering, CRISPR technologies and cancer research.

His research has helped identify new treatment targets, drivers of treatment resistance and accelerated the translation of discoveries into more effective, tolerable and accessible therapies for cancer patients.

With papers published in high-impact journals and involvement in the development of a novel targeted blood cancer treatment, his contributions to cancer care have been significant.

➡️ Read more: https://ow.ly/t9e650ZW8Am

🔬 Last week, we marked World Cancer Research Day by welcoming our local community into our laboratories.  Our talented r...
30/09/2026

🔬 Last week, we marked World Cancer Research Day by welcoming our local community into our laboratories.

Our talented researchers introduced our guests to nanomedicine, CAR T-cell therapy, powerful microscopy and more.

These are all tools and techniques that enable our team to advance their research 🧬

💛 Thank you to everyone who came! We are grateful for your support of our research and your keenness to learn what goes on inside a cancer research institute.

Thank you also to our wonderful team members who presented to our guests and gave demonstrations.

💌 Subscribe to our newsletter for updates about our next events: https://ow.ly/AgfZ50ZSuHM

Join us for a free Spotlight Series event hosted by our Patient Advocacy Network.  🔬 Are you interested in learning more...
30/09/2026

Join us for a free Spotlight Series event hosted by our Patient Advocacy Network.

🔬 Are you interested in learning more about the latest developments in breast cancer research?

🗣️ Do you have lived experience of cancer and would like to find out how you can use your voice to help advance research?

Then this event is for you!

Enjoy an evening of talks from our talented researchers, clinicians and dedicated patient advocates, with a focus on breast cancer.

📆 Thursday 15th October, 5:30pm–6:45pm

📍 ONJCRI, ONJ Centre, 145 Studley Road, Heidelberg, VIC

🎟️ To learn more and register, send an email to our friendly Patient Advocacy team at [email protected]

Spaces are limited, so we encourage you to register soon to not miss out. We look forward to welcoming you to the institute!

Dr Jean Berthelet is a Senior Postdoctoral Research Fellow tackling one of the biggest challenges in breast cancer: why ...
28/09/2026

Dr Jean Berthelet is a Senior Postdoctoral Research Fellow tackling one of the biggest challenges in breast cancer: why do some cancer cells go on to spread (metastasise) while others don't?

🔬 To answer this, Dr Berthelet uses cellular barcoding, a technique where individual cancer cells are tagged with unique genetic or fluorescent "barcodes".

A tumour is made up of hundreds of different cell types (clones). Some are responsible for tumour spread, and understanding their behaviour is crucial in developing more effective cancer treatments.

Cellular barcoding helps Dr Berthelet track individual cancer clones over time and space, revealing which ones are driving aggressive spread to sites like the lungs, liver and brain.

Using this approach, Dr Berthelet is investigating a protein that is consistently over-expressed in the most aggressive breast cancer clones that are prone to spreading. What is this protein’s role? Is it causing cancer spread?

"This is a largely understudied protein with no targeted therapies against it."

That makes it an exciting potential new drug target, one Dr Berthelet is now working to validate in patient samples:

"We want to go one step further and test this hypothesis using archival patient samples with annotated medical data. Due to the high heterogeneity and variability of breast cancer, many samples will be required to draw solid conclusions."

Dr Berthelet is excited about how this research could impact patients in future.

"In the shorter term, we think that this protein could be a way to highlight patients at higher risk of breast cancer recurrence, enabling earlier and more thorough follow-up on this population to catch the recurrence as early as possible.”

Dr Berthelet's work is a great example of how fundamental cancer biology can chart a path toward better outcomes for patients.

Address

145 Studley Road
Melbourne, VIC
3084

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+61394965726

Alerts

Be the first to know and let us send you an email when Olivia Newton-John Cancer Research Institute posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share